Human-protein CAR-T design avoids anti-drug antibodies and extends persistence
A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma.
Read original article on The Medical News →